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PEMILIHAN SECARA RASIONAL PENGHALANG PAM PROTON 
MELALUI SISTEM PENSKORAN OBJEKTIF UNTUK  
PENGURUSAN FORMULARI BERKESAN 
 
ABSTRAK 
 
Pemilihan ubat secara rasional adalah penting dalam pengurusan formulari yang 
berkesan.  Tujuan utama mewujudkan sistem penskoran objektif adalah untuk 
memberi garis panduan kepada doktor dalam penggunaan ubat yang telah dibuktikan 
oleh kajian klinikal dari segi keberkesanan, keselamatan dengan kos yang paling 
murah tanpa mempengaruhi tahap penjagaan pesakit. Dalam bahagian pertama, 
objektif utama kajian ini adalah mewujudkan satu sistem penskoran objektif untuk 5 
jenis penghalang pam proton iaitu esomeprazol, lansoprazol, omeprazol, pantoprazol 
dan rabeprazol dengan menentukan kriteria-kriteria yang sesuai dipertimbangkan 
serta diberi skor yang bersesuaian mengikut kepentingan kriteria tersebut dalam 
proses pemilihan penghalang pam proton dalam rawatan refluks gastroesofagus. 
Objektif bahagian kedua merupakan satu kajian kes untuk menganalisis penggunaan 
dan perbelanjaan penghalang pam proton di Hospital Serdang serta membuat 
perbandingan dengan keputusan yang diperolehi oleh sistem penskoran objektif.  
Bahagian ini juga menentukan langkah untuk menjimatkan kos penggunaan 
penghalang pam proton. Untuk bahagian pertama, kriteria yang dianggap tinggi 
kepentingannya akan diberi skor yang tinggi: 200 skor untuk dokumentasi, 300 skor 
untuk keberkesanan, 200 skor untuk keselamatan dan 300 skor untuk harga. Jumlah 
skor bagi sistem penskoran ini adalah 1000. Kaedah persampelan mudah telah 
digunakan untuk mendapatkan saiz sampel responden bagi kajian ini. Borang soal 
jawab telah diagihkan kepada 165 pakar perubatan dan pegawai perubatan klinik 
pakar di 6 hospital di Selangor dan Kuala Lumpur.  Untuk bahagian kedua, satu 
 xiv 
kajian restrospektif telah dijalankan. Semua preskripsi yang mengandungi ubat 
penghalang pam proton dari klinik pakar telah diperolehi dari Sistem Informasi 
Hospital Keseluruhan (THIS) . Bilangan preskripsi, penggunaan dan perbelanjaan 
penghalang pam proton juga dianalisis. Analisis lanjut telah dijalankan untuk 
menentukan potensi penjimatan kos dengan menggantikan esomeprazol, lansoprazol, 
pantoprazol and rabeprazol dengan omeprazol. Keputusan dari sistem penskoran 
objektif pada bahagian pertama dibandingkan dengan penggunaan penghalang pam 
proton di Hospital Serdang sama ada ia memenuhi jangkaan pengamalan klinikal di 
hospital. Untuk bahagian pertama, hanya 73 (44.2%) borang soal jawab dipulangkan 
lengkap. Pakar perubatan serta pegawai perubatan dikehendaki memberi skor 
mengikut pandangan dan pengalaman mereka terhadap kepentingan kriteria – kriteria 
tersebut. Keputusan menunjukkan omeprazol merupakan penghalang pam proton 
yang mendapat skor tertinggi, diikuti oleh lansoprazol dan pantoprazol. Bahagian 2 
mendapati penggunaan omeprazol adalah tertinggi (70.41%), diikuti oleh 
pantoprazol (13.49%) dan esomeprazol (12.78%). Dari segi perbelanjaan, pembelian 
omeprazol adalah sebanyak 39.14% daripada perbelanjaan keseluruhan penghalang 
pam proton, diikuti oleh pantoprazol (29.24%) dan esomeprazol (27.54%). Sebanyak 
RM 330,000.00 telah dibelanjakan untuk membeli penghalang pam proton di 
Hospital Serdang pada tahun 2009. Penjimatan kos sebanyak 44.4% dapat dilakukan 
jika semua ubat penghalang pam proton digantikan dengan ubat generik omeprazol. 
Sistem penskoran objektif terbukti dapat membantu dalam pemilihan ubat secara 
objektif, berkesan dan sistematik. 
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RATIONAL SELECTION OF PROTON PUMP INHIBITORS (PPIs) 
THROUGH AN OBJECTIVE SCORING SYSTEM FOR EFFECTIVE 
FORMULARY MANAGEMENT 
 
ABSTRACT 
 
Rational drug selection is fundamental for effective formulary management. The 
rationale of an objective scoring system is to establish and make available drugs 
which are proven to be the most efficacious, safe and cost-effective without 
compromising the quality of patient care. The aims of Part 1 of the study were to 
develop an objective scoring system by determining the criteria for 5 available PPIs 
i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole as well as 
to assign scores according to the importance in the evaluation process for the 
inclusion and exclusion of PPIs for the indication of GERD. Part 2 of the study was a 
case study aim to review and compare the usage and expenditure of PPI drugs used 
in Serdang Hospital with the most preferred PPI obtained in Part 1 of the study. This 
study also aims to determine appropriate cost saving measure in the treatment of acid 
related disease requiring PPIs.  In the first part of the study, the higher the assigned 
score, the higher importance the criterion is. Two hundred were assigned to 
documentation, 300 points for efficacy, 200 points for safety and 300 points for cost.  
Total points were 1000.  A convenience sampling method was used to generate the 
sample size of the participants in this survey. Self-administered questionnaire was 
distributed to 165 specialists / lecturers and medical officers in various out-patient 
clinics in 6 selected hospitals in Selangor and Kuala Lumpur.  In the second part of 
the study, a retrospective study was carried out to review all prescriptions containing 
PPI drugs prescribed by the medical, gastroenterology, surgical, nephrology and 
cardiology out-patient clinics in Serdang Hospital. The number of prescriptions, 
 xvi 
usage and expenditure of PPI drugs were analyzed. Further analysis were undertaken 
to estimate the potential savings that could be achieved by replacing esomeprazole, 
lansoprazole, pantoprazole and rabeprazole with the generic brand omeprazole. Out 
of 165 questionnaires distributed, only 73 questionnaires were successfully 
completed and returned (response rate = 44.2%). The scoring system showed that 
omeprazole was the most preferred PPI, followed by lansoprazole, pantoprazole, 
esomeprazole and rabeprazole.  The expenditure of all PPIs available in Serdang 
Hospital in 2009 was RM 330,000.00. Omeprazole (70.41%) was the most 
commonly used, followed by pantoprazole (13.49%) and esomeprazole (12.78%). 
Omeprazole contributed 39.14% of the total spending of all PPIs, followed by 
pantoprazole (29.24%), esomeprazole (27.54%). It was found that 44.4% of the PPI 
expenditure could be saved when all PPIs were substituted with the generic brand 
omeprazole. The scoring system allows drug selection to be done in a more 
objective, transparent and systematic way.   
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CHAPTER ONE 
 
 
INTRODUCTION 
 
1.1  Introduction 
The cost of healthcare budget in developed countries is increasing at an alarming rate 
(Heginbotham, 1992). The total value of drugs procured for the use in all hospitals 
and health clinics in Malaysia for 2008 was RM 1,510 million, an increase of 397% 
compared to RM303.8 million in 1998 (MOH, 2008). Cost containment measures 
have to be considered to overcome the high drug procurement cost. Having a reliable 
yet comprehensive drug formulary is one way to promote rational prescribing and to 
limit costs (Schwartz & Aeron, 1984).  
 
The need of a National Drug Formulary is crucial for promoting rational and cost-
effective use of medicines in hospital as the formulary will usually cover 80% of all 
prescribing decisions (Karr, 2000). It also helps in solving pharmaceutical problems 
recognized in most pharmaceutical system such as limited drug budgets, increasing 
number of therapeutic alternatives, improper use of medications in prescribing and 
high cost of handling large number of drugs of questionable quality in the market 
(Savelli et al., 1996). 
 
The National Drug Formulary in Malaysia clearly defined the type and choice of 
drugs approved for use in all hospitals under the umbrella of the Ministry of Health 
to ensure uniformity and equity across all hospitals in Malaysia.  
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In most countries like the UK and The Netherlands, drugs selected in the National 
Drug Formulary were based on evidence-based clinical effectiveness, safety, 
tolerability and the selection of the minimum number of drugs needed to treat the 
prevalent disease. Selection of drugs were also based on clinical practice guidelines 
(CPG) of the disease. The inclusion of new drugs are only considered if they were 
found to have distinct advantages over drugs currently in use or at a lower cost 
(LeRoy & Morse, 1983). 
 
In Malaysia, the Ministry of Health Drug List Review Panel consists of pharmacists 
and senior consultants and assisted by 17 Technical Drug Working Committees from 
various specialized disciplines. These panels will meet, review and update the drugs 
listed in the formulary two to three times a year and at the same time evaluate the 
proposals for additions or deletions of drugs in the drug  formulary upon application 
from the state drug commitee. The applicants are required to put forward the 
application for i) Proforma A which is a proposal to delete any of the drug / dosage 
form / formulation in the MOH Drug Formulary, or ii) Proforma B which is a 
proposal to alter / add formulation / dosage form / category of the prescriber / 
indication in the MOH Drug Formulary or iii) Proforma D which is a proposal to 
introduce new drugs into the MOH Drug Formulary. The state drug commitee 
meeting will first review and recommends these proforma by forwarding the 
application to the Secretariat of the Ministry of Health Drug List Review Panel. The 
applicant would have to provide a comparative study between the new drugs and 
drugs which are already available in the MOH Formulary based on its efficacy, 
safety, tolerability and cost – effectiveness criteria. Applicants were also required to 
provide studies / trials with respect to the above criteria. This is to ensure all drugs 
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available in the National Drug Formulary were comprehensive and evidence-based. 
The proforma will then be reviewed by the Ministry of Health Drug List Review 
Panel. To further enhance a more objective and transparent drug selection process, an 
analytical scoring system should be developed to assist the process of drug 
evaluation and selection of drugs. 
 
A scoring system is needed to enable the Pharmacy and Therapeutic (P&T) 
committee to objectively appraise and evaluate each drug when performing drug 
reviews such as in developing new drug monographs, re-evaluation of previous 
formulary decisions periodically or whenever there are changes in the clinical 
practice guidelines and therapeutic class review in a more reliable manner without 
any biasness or preferences. The P&T drug committee will then be able to make 
better and speedier decisions in the selection of all therapeutic class of drugs for the 
most efficacious, safe and cost effective drugs determined from an objective scoring 
system.  
 
Many drugs selection tools have been developed and used for formulary purposes 
(Karr, 2000; Moore et al., 2002). Pharmaceutical Product Drug Differential 
Evaluation (PPDEM), Comparative Utilisation of Resource Evaluation Model 
(CURE), Formulary Analysis and System of Objectified Judgement Analysis (SOJA) 
are all drug selection tools in which drugs entity from the same therapeutic class are 
differentiated in terms of its efficacy, safety, side effects, patient compliance and 
price (Janknegt et al., 1997; Karr, 2000; Moore et al., 2002).  
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The methods from the above tools in particularly System of Objectified Judgement 
Analysis (SOJA) were adopted in the development of this scoring system. In this 
study, the criteria were adapted from various drug selection methods to develop a 
scoring system appropriate to evaluate the therapeutic group of Proton Pump 
Inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD). 
Prevalence rate of GERD in Malaysia has been estimated at 13.4% (Goh, 2004), 
while the prevalence of this disease in the UK and USA had been estimated to be 
about 29–44% (Dent, 2005). GERD is currently the most common among acid 
related disorders and an increased in prevalence is anticipated both locally in 
Malaysia and globally. 
 
 
All PPIs that are available in Malaysia were included in the analysis i.e. 
esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. The PPI 
group of drugs were chosen because there has been a rapid increase in PPI drugs 
prescibing in Malaysia and therefore rational prescribing and cost containment 
measures are needed. Among the top 40 drugs utilised, omeprazole was ranked the 
fourth highest expenditure with RM33,056.4 million.  Drugs for acid related 
disorders ranked 6th in the ranking of expenditure on therapeutic drug groups (Goh, 
2004).  
 
1.2 Problem Statement 
There is no scoring system currently being used in Malaysia to evaluate drugs for the 
inclusion and exclusion in the drug formulary. Drug selection without a scoring 
system can lead to bias selection of drugs, influenced by the pharmaceutical 
company‟s advertisements and the preference of certain drugs by the drug commitee. 
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Another problem is that the prescribers were faced with difficult choices on the 
selection of  PPI drugs made available to their patients. A scoring tool is necessary to 
help the drug committee make better decision on drugs selection in order for PPIs to 
be evaluated and reviewed in a more consistent and systematic approach (Janknegt et 
al., 1997). The scoring system can play its role as a check-list for the drug committee 
to review and update drugs in the Drug Formulary. 
 
With a scoring system developed and available for every therapeutic drug class ready 
in hand, new information on drugs can be easily updated. Therefore, DESS is a 
flexible model that can compare and update current drugs updates for each 
therapeutic class of drugs easily and rapidly in order to keep the evaluation process 
„live‟ (Karr, 1994).  
 
The cost of health care budget in developed countries is increasing at an alarming 
rate. Pharmaceuticals comprise of up to RM 1,510 millon yearly in Malaysia, (MOH, 
2008) and it is projected to increase 13% - 15% annually. Overcoming these cost is 
becoming more difficult and many cost containment measures are being considered. 
One of the measures that can overcome the high expenditure of drugs is to restrict the 
number of drugs within the same therapeutic class (Kessler, 1994). The selection of 
drugs can be done in a more objective and systematic approach by using an objective 
scoring system which is able to differenciate and to compare important criteria such 
as clinical documentation, clinical efficacy, clinical safety and acquisition cost for 
each drugs belonging to the same therapeuctic class as well as for any new inclusion 
of drugs in the formulary.  As in this case, the scoring system was use to evaluate all 
the available PPI drugs and to select the most preferred PPI which was proven to 
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have the highest clinical effectiveness with the least safety issues and lowest cost to 
be included in the Drug Formulary. 
 
Irrational prescribing of drugs is a common occurrence in clinical practice. It was 
shown that the average number of occurrence for poly-pharmacy was 3.8 per case 
per episode for both population of children and adult group (Laing, 1990).  Irrational 
drug prescribing will cause failure in achieving therapeutic goals and hence 
contribute to higher drug expenditure. Rational prescribing of PPIs is defined as 
receiving medications appropriate to the patient‟s clinical needs, in doses that meet 
individual requirements for an adequate period of time, and at the lowest cost (Dott 
& Johnson, 1999). The Drug Formulary is one measure to encourage appropriate 
prescribing as all drugs selected to be in the formulary are clinically proven and 
carefully selected to be the most cost-effective drugs. Prescribers are strictly 
encouraged to adhere and to prescribe only from the selection of drugs available in 
the drug formulary. 
 
 
1.3 Study Justification 
This study focused on developing a scoring system which consists of a list of criteria 
and assigning weightage to each criterion and sub-criterion for the rational selection 
of PPIs. A scoring system is required to assist the drug committee in the inclusion 
and exclusion of drugs in the drug formulary so that drugs can be selected in a more 
consistent and objective approach.  PPIs were used as a platform to assess the Drug 
Evaluation Scoring System (DESS). The PPIs group was chosen as it has been 
proven to be more superior to H2 - receptor blockers (H2RAs) in the treatment of 
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GERD (Chiba, 1997) and the usage of PPI drugs in the government hospital has 
recorded an upwards trend with the PPI drug class ranked 9th with a total spending 
of RM 18,413,000.00 in 2006 and ranked 8th with a total spending of RM 29, 
434,000.00 in 2007 in the top 10 therapeutic group by expenditure (Malaysian 
Statistics on Medicine, 2007). The scoring system can be used to re-evaluate the 
same therapeutic group of drugs when new data or new drugs emerge or it can be 
extended to other group of drugs with the appropriate criteria selected in the near 
future. 
 
The scoring system can also be used to evaluate newly marketed drugs, where 
comparison can be easily made in terms of its experience with the drugs, clinical 
efficacy, safety and cost. This is to evaluate if a drug is good enough or better than 
the available drugs already listed in the national drug formulary. There is no need to 
include a newly marketed drug from the same therapeutic class if the drug was found 
to be of equivalent in clinical efficacy and safety which usually comes at a higher 
price. Restricting the number of drugs in the same group class in the drug formulary 
can prevent poly-pharmacy which can lead to irrational prescribing. This study is 
important as limiting the number of drugs for the same indication in the Drug 
Formulary will help to reduce the government‟s expenditure on drugs. 
 
An objective scoring system would be able to help the drug committee and 
physicians to make better, unbias and reliable choice of drugs for their patients, and 
hence promote rational use of drugs. This is vital to ensure quality, efficacy and safe 
drugs to be used on patients at the most affordable cost. 
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1.4  Objectives 
Based on the problem statement and study justification mentioned previously, this 
study was conducted with the general aims of developing and initiating an objective 
and transparent scoring system intended for promoting rational selection of all 
therapeutic class of drugs in the Ministry of Health. 
The specific objectives of the study were: 
1) To determine the list of criteria that can be used as a scoring system for the 
inclusion and exclusion of Proton Pump Inhibitors (PPIs) in the Drug 
Formulary for Gastroesophageal Reflux Disease (GERD). 
2) To determine the weightage for the selected criteria and sub-criteria of Proton 
Pump Inhibitors (PPIs) to be used as a scoring system. 
3) To determine the scores obtained for each PPI drugs and to rank these PPIs 
from the most preferred to the least preferred sequence. 
4) To reduce the number of Proton Pump Inhibitors (PPIs) in the Drug 
Formulary using the ranking of the scoring system. 
5) To evaluate and compare the usage and expenditure of all PPI drugs 
prescribed in Serdang Hospital with the array of the most preferred Proton 
Pump Inhibitor (PPIs) based on the scores obtained from the scoring system. 
6) To propose cost saving measures in the treatment of patients requiring Proton 
Pump Inhibitor (PPIs) therapy. 
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1.5 Contribution of the Study Findings 
Developing an objective scoring system is very important for rational selection of 
drugs. The study finding is crucial for the prospect of drug expenditure in the 
government sector, it also provides an objective system to evaluate the characteristics 
of drugs as well as provide useful drug information for healthcare providers and the 
patients. Physicians always believe they are prevented from prescribing the 
medications which their patient needs while patients believe they are being denied 
access to the drugs they deserve. A sound and reliable Drug Formulary is the solution 
to put an end to this dispute and prevent against unnecessary purchase of drugs in 
hospitals under the MOH.  
 
The P&T drug committee will benefit, as having an objective yet transparent scoring 
system will prevent the committee from making any unbiased drug selection to be 
listed in the Drug Formulary. There will be less scrutiny from doctors as the criteria 
in the decision making process can be revealed specifically if required. Selecting the 
right choice of drugs to be included into the Drug Formulary will help in reducing 
the drugs inventory and subsequently help to better manage stocks and drugs 
procurement for the purchasing pharmacists in the government hospitals. Well-
managed drug procurement should contain only restricted number of drugs for the 
same indication. Drugs having only marginal difference or equivalent in clinical 
effectiveness and safety profile from the same therapeutic class should not be 
selected and should be excluded, an approach which can help the Malaysian 
government to save on drugs expenditure, as the government is finding it hard to 
cope with the escalating drug cost. With the development of a scoring system, the 
drug committee can continuously evaluate and update drugs already in the formulary, 
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whenever there is any update in clinical practice guidelines (CPG) which can bring to 
a change in the prescribing pattern. Drugs which are no longer in use in the clinical 
practice guidelines should be reviewed and removed from the Drug Formulary. This 
will promote rational prescribing among physicians. By having only limited number 
of drugs from the same therapeutic class in the Drug Formulary, this will contribute 
to lesser irrational prescribing such as poly-pharmacy, hence achieving higher 
pharmacotherapeutic success for patients. The Drug Formulary generally provides 
useful comprehensive information for all drugs made available in the MOH, as a 
reference to all healthcare providers. A drug formulary also allows the doctors to 
develop better knowledge of a limited range of drugs which may lead to increase 
monitoring of drug therapy and improved patient care. It is hoped that the scoring 
system would be able to help to optimize PPI prescribing with the most economical 
agent. 
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CHAPTER TWO 
 
 
LITERATURE REVIEW: 
 
DEVELOPING A RATIONAL DRUG SELECTION TOOLS 
FOR FORMULARY MANAGEMENT 
 
The main goals of developing a Drug Formulary are to develop and implement 
policies on drug selection, evaluation, procurement, use of safe drugs and to 
disseminate reliable drug information to optimize patient care through rational 
selection and use of drugs. A drug formulary is used to ensure quality drug use and 
cost effective prescribing among physicians (Savelli et al., 1996).  
 
 
The rapidly rising cost of drug therapy is a concern to healthcare provider in 
developing countries such as Malaysia. At least RM 1,510 million was spent 
annually in the procurement of drugs alone for the public hospitals throughout 
Malaysia (MOH, 2008). The government is finding it hard to subsidize this large 
spending. The introduction of new drugs which frequently offer only marginal 
improvements over existing therapies but at substantially increased cost does 
contribute to the heavy spending on drugs (Kessler et al., 1994). One means of 
controlling the overall drug expenditure is through the development of drug 
formulary. Rational selection of drugs through a structured and stringent selection 
process will only allow medications which are listed to be prescribed.  Reducing the 
number of drug entities of the same therapeutic class with only slight differences in 
terms of clinical effectiveness and adverse effect can further help in containing cost 
(WHO, 2003). 
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2.1 Therapeutic substitution 
A study on preferential listing of a single drug within a drug class was done in the 
Canada Forces (CF) in 2003 to control drug procurement cost. An observational 
cohort study was performed using the database in the Canadian Forces Pharmacy and 
a total number of 4738 PPI users who receive more than 1 PPIs between 1 January 
2004 – 31 December 2004 were evaluated to explain the usage pattern of PPIs. The 
study selected pantoprazole as the most preferred agent in the PPI class based on 
clinical evidence, availability of dosage forms and costs while removing 
esomeprazole, lansoprazole, omeprazole and rabeprazole from the CF Drug Benefit 
List. Studies showed that very marginal difference in efficacy exist between PPIs 
when prescribed at equivalent doses (Amidon et al., 2000; Gearson et al., 2000). In 
the study, 87% (n=4112) were prescribed pantoprazole while 13.2% (n=626) 
received other PPIs. The reasons for those prescribed with other PPI drugs other than 
pantoprazole were „failure to respond‟, and side effects with pantoprazole. The CF 
Pharmacy spent Can$ 214,451.98 for the year from 2003 to 2004 for pantoprazole 
alone, taking over 50% of cost associated with the PPI class of Can$431,504.42 
which includes PPI drugs other than pantoprazole and the stocking up of intravenous 
pantoprazole in standardized military medical kits for use during deployment (Ma et 
al., 2008). Therefore, cost savings with therapeutic substitution will only be achieved 
with stringent policies and full compliance from physicians. 
 
 
2.2 Drug Formulary 
 
 
The conventional way of developing a formulary system usually involve a process 
whereby the medical staff of an institution, working through a Formulary and 
Therapeutics Committee, manages, evaluates and selects from the numerous 
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available drug products that are considered most efficacious, safe, and cost effective. 
It is a mechanism to streamline procurement activities, minimize costs and optimize 
patient care (Savelli et al., 1996).  
 
The MOH Drug Formulary is one example of drug formulary developed using the 
conventional method. The MOH Drug Review Panel which comprise of the Director 
General of Health Malaysia (chairman), the Deputy Director General of Health 
(Medical Services), the Director of Pharmaceutical Services, 8 Consultants in Public 
Service, 2 Pharmacists in Public Service and a Senior Pharmacist in Public Service 
(secretary) will review and update the drugs listed in the formulary from time to time 
to ensure that a comprehensive, evidence-based and dynamic list of drugs is available 
for prevention and treatment of patients. The MOH Drug List Review Panel will 
meet two to three times per year to consider proposals received from the State / 
Institution Drug committees. The panel is assisted by 17 Technical Drug Working 
Committees from various specialised disciplines (MOH Drug Formulary Manual, 
2008). The existing formulary system employs a disadvantageously very time 
consuming and not so transparent procedure to complete an approval and / or 
disapproval application. 
 
In order to make the existing process to be more objective and transparent, a flexible 
and rational tool that exclude emotional factors, advertising influence or even cost 
interest can be develop. This tool can be used for any evaluation that requires re-
assessment with time or provides ease of updating to accommodate changes in the 
context in which selection decisions are being made. This tool will be of great help to 
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the Formulary and Therapeutics Committee especially in drugs decision process as it 
becomes clear on which criteria the decisions are based on.  
 
 
 
 
2.3  Drug selection system 
 
Many drugs selection tools such as the Pharmaceutical Product Drug Differential 
Evaluation (PPDEM), Comparative Utilization of Resource Evaluation Model 
(CURE), System of Objectified Judgement Analysis (SOJA) and Formulary Analysis 
have been developed and used for formulary purposes worldwide (Janknegt et al., 
1997; Karr, 2000; Moore et al., 2002).  
 
 
Drug selection methods should be able to aid in providing optimal drug therapy to all 
patients through the development of standard treatment guidelines, to objectively 
evaluate clinical data of new drugs proposed for use in hospitals, to prevent 
unnecessary duplication of drugs, to develop list of drugs accepted for procurement 
and use in the hospital, to recommend and approve additions and deletions from the 
formulary and to conduct ongoing drug use evaluation programs (Savelli et al., 
1996). 
 
 
PPDEM is an analytical tool to support evaluations on drugs selection. PPDEM is 
usually used to distinguish selection criteria of drugs belonging to the same 
therapeutic class of drugs which were used to treat a particular prevalent disease 
(Karr, 1994; Rawlins, 1999). 
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CURE is a similar flexible model for drugs evaluation and selection that can 
differentiate drugs within the same therapeutic class which includes criteria such as 
efficacy, safety, side effects and cost. The advantage of CURE over PPDEM is the 
inclusion of an additional criterion called climate for change. Climate for change 
includes the experience factor of the prescriber, hospital readiness to change to a new 
drug, patient acceptability of changing to new drugs when the current drugs works 
well on them, resource benefit where by changing to a new drug with only marginal 
cost savings is gained and frequency of review especially when new drugs are 
launched at a fast pace, the susceptibility of the prescriber and patient to alter the 
prescribing practice.  CURE model provides decision makers with an analytical tool 
to support evaluations on drug selections and also intended to stimulate discussion or 
debate by decision makers and may assist in providing a suitable mechanism for 
producing the decision itself. CURE model is auditable, flexible and it 
accommodates changes.  
 
 
A Formulary Analysis on angiotensin receptor blockers (ARBs) was done in the 
Sheffield Teaching Hospital Trust, England. Six ARBs which consist of 
candersartan, eprosartan, irbersartan, losartan, telmisartan and valsartan were 
reviewed and evaluated by a panel of cardiologists, a physician and a pharmacist. 
Nine selection criteria were developed as a comparison framework between these 
drugs. A relative weight was assigned to each criterion by the panel. Each ARB was 
systematically evaluated against each criterion and scores were calculated. Results 
obtained were presented and recognized by the hospital‟s P&T committees. Losartan 
was ranked the highest (707), followed by valsartan (611) and candersartan (610) 
(Moore et al., 2002). 
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Another structured approach to the selection of drugs for formulary inclusion was of 
System of Objectified Judgement Analysis (SOJA) which was first developed in The 
Netherlands for the evaluation of hypnotics, NSAIDs and ARBs. The criteria 
included in the method for hypnotics drugs selection were clinical efficacy (300 
points), adverse effects (250 points), clinical documentation (150 points), cost (120 
points), pharmacokinetic properties (80 points), toxicity (50 points), drug interactions 
(30 points) and the number of tablet strengths available (20 points). 
 
A slight modification of the SOJA system was then developed which was tested on 
the selection of ACE Inhibitors (ACEIs) in Northern Ireland. ACEIs included in the 
study were captopril, cilazapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, 
perindopril, quinalapril and trandolapril. The relative weighting for each drug were 
assigned to each criterion and were determined by a panel of expert which consisted 
of a consultant cardiologist, a general practitioner, two pharmacists, a regional 
pharmaceutical procurement manager, a hospital pharmaceutical services manager 
and a health economist. The selection criteria for ACEI were based on evidence 
based pharmacotherapeutic evaluation for all the ACEIs, safety and cost impact. 
Relative weightings were then assigned to the criteria by the expert panel. The 
resultant scoring system containing the selection criteria as well as the weighting 
scores was validated by 103 key decision makers and secondary care consultants in 
Northern Ireland, the association of British Pharmaceutical Industry, the British 
General Manufacturing Association and the Parallel Pharmaceutical Distribution 
Industry. These prescribers were asked to comment on the allocation of the scores 
and to change the scores and give importance to the criteria by adding and removing 
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criteria. The last step involved scoring of the individual ARBs by 33 expert panels (7 
cardiologists, 6 nephrologists, 8 pharmacists 2 endocrinologists, 2 internal medicine 
consultants, 1 senior geriatrician and 7 decision makers) using published literature as 
well as from both proprietary and generic manufacturers within the class of ACEIs. 
Only 5 ACEIs i.e. trandolapril, lisinopril, ramipril, enalapril, fosinopril scored the 
highest and were included in the drug formulary. Modified SOJA allows drug 
selection within a drug class across a range of indications and confers clinical 
effectiveness primacy over cost (Alabbadi et al., 2006).  
 
SOJA, modified SOJA, Formulary Analysis, PPDEM and CURE are scoring systems 
that can be used to evaluate and then re-evaluate drugs in the same therapeutic class 
whenever there is new update on the drugs (Karr, 1994; Rawlins, 1999; Janknegt et 
al., 1997). The summary of each tools were demonstrated in Tables 2.1, 2.2 and 2.3. 
Table 2.1: Comparison between drug selection methods in terms of criteria 
Drug Selection Method Criteria 
PPDEM Efficacy, safety, cost 
CURE Efficacy, safety, cost, climate for changes 
Formulary Analysis Efficacy, safety, cost 
SOJA Documentation, efficacy, safety, cost 
MOH Drug Formulary Efficacy, safety, cost 
 
Table 2.2: Comparison between drug selection methods in terms of evaluator 
Drug Selection Method Evaluator 
PPDEM Expert panel which consists of consultants and 
healthcare providers 
CURE Expert panel which consists of consultants and 
healthcare providers 
Formulary Analysis Expert panel which consists of consultants and 
healthcare providers 
SOJA Expert panel which consists of consultants and 
healthcare providers 
MOH Drug Formulary Expert panel which consists of consultants and 
healthcare providers 
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Table 2.3: Comparison between drug selection methods in terms of weightage 
Drug Selection Method Scores 
PPDEM Arbitrary; Depend on the degree of importance in 
the evaluation process. The more important criteria 
will assigned a higher score.  
Total score:100 
CURE Arbitrary; Depend on the degree of importance in 
the evaluation process. The more important criteria 
will assigned a higher score. 
Total score: 100 
Formulary Analysis Arbitrary; Depend on the degree of importance in 
the evaluation process. The more important criteria 
will assigned a higher score. 
Total score:1000 
SOJA Arbitrary; Depend on the degree of importance in 
the evaluation process. The more important criteria 
will assigned a higher score.  
Total score: 1000 
MOH Drug Formulary Highly dependent on panelists‟ experiences, 
evidence-based information 
No score points. 
 
 
2.4 Gastroesophageal reflux disease (GERD)  
GERD is the retrograde movements of gastric contents from the stomach into the 
esophagus which can cause inflame and damage to the lining of the esophagus. The 
regurgitate liquid usually contains acid and pepsin. GERD symptoms can vary from 
mild to severe; from typical symptoms include heartburn, belching, hypersalivation, 
and regurgitation without endoscopically demonstrated esophagitis, to severe 
esophageal mucosal damage such as peptic stricture and Barrett‟s metaplasia 
(Devault & Castell, 1999). 
 
The normal function of lower esophagus sphincter (LES) is to produce contraction 
and closing of the passage from the esophagus into the stomach. This closing 
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prevents reflux. When food is swallowed, the LES relaxes for a few seconds to allow 
the food to pass from the esophagus into the stomach, and then contracts and closes 
again. Weak contraction of the LES and transient LES relaxation which caused 
abnormal relaxation of LES are dysfunctions of the LES that cause GERD. Other 
factors that may contribute to GERD are hiatal hernias, pregnancy and obesity 
(Devault & Castell, 2005). 
The goals of treatment for GERD include: 
i. relieving symptoms 
ii.  healing of esophagitis  
iii. prevent further symptoms and complications.  
iv. prevention and recurrence of the disease 
There are two grading scheme that has been used in endoscopic assessment in 
comparative clinical studies. The Savary-Miller grading scale is the most commonly 
applied while the Los Angeles (LA) scale is the most often used grading scale for 
reflux esophagitis. Table 2.4 and Table 2.5 are the classifications of the grading 
scheme for the Savary-Miller grading scale and the LA scale: 
Table 2.4: The Savary – Miller classification of reflux esophagitis 
Grade Descriptions 
I Single erosion above gastro-esophageal mucosal junction 
II Multiple, non- circumferential erosions above gastro-esophageal 
mucosal junction 
III Circumferential erosions above mucosal junction 
IV Chronic change with esophageal ulceration and associated 
stricture 
V Barett‟s esophagus with histologically confirmed intestinal 
differentiation with columnar epithelium 
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Table 2.5: The LA classification of reflux esophagitis 
Grade Descriptions 
A One or more mucosal break not longer than 5 mm, that does not 
extend between the tops of two mucosal folds 
B One or more mucosal break more than 5 mm long that does not 
extend between the tops of two mucosal folds 
C One or more mucosal break that is continuous between the tops of 
two or more mucosal folds but involves less than 75% of the 
circumference 
D One or more mucosal break which involves at least 75% of the 
circumference 
(Gut. 1999; 45:172-180 Lundell et al., 1999) 
 
2.5 Clinical Practice Guidelines 
As stated in the 2004 Asia-Pacific Consensus on the management of GERD, lifestyle 
modifications are commonly used as first line of therapy in patients presenting with 
GERD-related symptoms. They include weight loss, smoking cessation, avoidance of 
postprandial recumbency for a period of at least 3 hours, elevation of the head of the 
bed, avoidance of tight-fitting garments, and avoidance of large heavy meals as well 
as food and drink that exacerbate GERD symptoms (e.g. spicy foods, fatty meals, 
peppermint, chocolate, onions, citrus juices, and carbonated beverages) (DeVault & 
Castell, 2005) 
 
PPIs are the most efficacious medical intervention for GERD. Studies have shown 
repeatedly and consistently that PPIs are superior to H2-receptor antagonists (H2RAs) 
in healing the esophageal mucosa and relieving GERD related symptoms of patients 
with ERD (Caro et al., 2001). In a meta-analysis, the authors demonstrated that after 
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12 weeks of treatment, healing rates were 83.6% with PPIs, 51.9% with H2RAs, 
39.2% with sucralfate, and 28.2% with placebo (Chiba et al., 1997). In addition, 
treatment with PPIs resulted in healing rates of esophageal inflammation and relief of 
heartburn symptoms that were two-fold higher than what was observed in patients 
receiving H2RAs. Similarly, PPIs demonstrate superiority in relieving heartburn 
symptoms in patients with NERD when compared to H2RAs (Richter et al., 2000). 
 
According to NICE guidance for dyspepsia (2004), patients who are present with 
typical GERD symptoms should be started on full dose PPI for 4 – 8 weeks.  If 
patients have severe esophagitis and remain symptomatic, double-dose PPI for a 
further 4 weeks may increase the healing rate. PPIs appear more effective than 
H2RAs in endoscopy-negative reflux disease. For recurring symptoms, a PPI at the 
lowest dose possible should be given to control symptoms, with a minimum number 
of repeat prescriptions. PPIs are more effective than H2RAs at maintaining against 
relapse of esophagitis in trials of 6–12 months duration (NICE, 2004). 
 
American Gastroenterology Association (AGA) drew the same guidelines and it was 
adopted by the National Guidelines Clearinghouse on GERD that lifestyle 
modifications should be recommended throughout the treatment of GERD. This is 
followed by pharmacological treatment such as H2-receptor antagonists (H2RAs), 
proton pump inhibitors (PPIs), and prokinetics. For non-erosive reflux disease 
(NERD), step-up (H2RAs followed by a PPI if no improvement) and step-down (PPI 
followed by the lowest dose of acid suppression) therapy are equally effective for 
both acute treatment and maintenance. On-demand (patient-directed) therapy is the 
most cost-effective strategy. For erosive esophagitis, initial PPI therapy is the 
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treatment of choice for acute and maintenance therapy for patients with documented 
erosive esophagitis. Antireflux surgery is an alternative modality in the treatment of 
GERD in patients who have documented chronic reflux with recalcitrant symptoms 
(DeVault & Castell, 2005). 
 
2.6 Pharmacology of PPIs 
All PPIs are substituted benzimidazoles that suppress the final step in gastric acid 
secretion by binding to the proton pump (H
+
/K
+
-ATPase enzyme system) on the 
gastric parietal cell. The proton pump inhibitors are given in an inactive form. In an 
acidic environment, the inactive drug is protonated and rearranges into its active 
form. The active form will covalently and irreversibly bind to the gastric proton 
pump, deactivating it. Minor differences exist among PPIs with respect to the 
mechanism of action within the parietal cell (Vanderhoff & Tahboub, 2002). 
Rabeprazole forms a partially reversible bond with the proton pump (Vanderhoff & 
Tahboub, 2002). Pantoprazole preferentially binds avidly to an additional acid 
inhibiting cycteine residue located deep within the membrane which greatly impairs 
the reversibility of bindings and prolongs duration of action (Welage & Berardi, 
2000). Once inhibition occurs, recovery can only occur with regeneration or 
resynthesis of new ATPase. Recovery is therefore generally a relatively slow process 
compared with the initial inactivation (Fock et al., 2008). 
 
2.7 Pharmacokinetics of PPIs 
Table 2.6 showed the pharmacokinetics of the five PPI drugs. The absolute 
bioavailability ranges from 35% for a single dose of omeprazole to 90% with repeat 
administration of esomeprazole. Unlike other PPIs, the bioavailability of rabeprazole 
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remains unchanged with repeated dosing. On the whole, the time to reach the peak 
plasma concentration (tmax) is about 2 hours. After absorption into the circulation, 
PPIs are taken up preferentially by gastric parietal cells, especially when they are 
actively secreting acid. Once inhibition occurs, recovery can only occur with 
regeneration or resynthesis of new ATPase. These mechanisms suggest that despite 
the short elimination half-lives, the biological effect persists for much longer (Fock 
et al., 2008). 
 
 All PPIs are extensively protein bound and undergo hepatic metabolism via the 
cytochrome CYP-450 pathways and the isoforms CYP2C19 and CYP3A4. 
Esomeprazole is the S-isomer of omeprazole, which is a racemic mixture of two 
optical isomers, the R- and S-isomers. However, esomeprazole and the omeprazole 
differ in the ratios in which they are metabolised by CYP2C19 and CYP3A4. 
Esomeprazole is metabolised to a greater extent by CYP3A4 than omeprazole and to 
a lesser extent by CYP2C19 (Abelo et al., 2000). The metabolism of rabeprazole 
does not appear to be significantly affected by CYP2C19 where in one particular 
study on rabeprazole showed similar healing rates at 4 and 8 weeks were obtained in 
extensive metabolisers (EMs), intermediate metabolisers (IMs) and poor 
metabolisers (PMs) (Ariizumi et al., 2004), whereas for omeprazole, lansoprazole 
and pantoprazole, a marked difference in metabolism exists between EMs and PMs 
(Ishizaki & Horai, 1999). At 4 weeks, the healing rates were 57.1%, 69.2% and 
72.7% in EM, IM and PM, respectively, while the healing rates at 8 weeks were 
77.4%, 95.0% and 100%, respectively (Kawamura et al., 2003). These differences in 
polymorphisms affect the metabolic and pharmacokinetic profiles of PPIs and may 
influence the therapeutic effectiveness. Esomeprazole has a lower total intrinsic 
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clearance than omeprazole, and its first-pass metabolism is decreased compared with 
omeprazole. The advantageous metabolism of esomeprazole results in higher area 
under the plasma concentration-time curve (AUC) values than those for omeprazole 
at the same dose, and hence may achieve better acid suppression than omeprazole in 
clinical practice (Fock et al., 2008). 
 
Rabeprazole, lansoprazole and pantoprazole have similar bioavailability on days 1 
and 5. The bioavailability of omeprazole increases 1.5 to 2 fold at day 5, while that 
of esomeprazole increases 3 fold at day 5 (Hellstrom & Vitols, 2004). 
 
The currently available PPIs have short elimination half-lives ranging from 1 to 1.5 
hours. A PPI with a longer elimination half-life may produce more prolonged 
blockade of proton pumps with the potential for greater acid suppression and, hence, 
a greater clinical effect, particularly for patients with significant postprandial evening 
and/or nocturnal symptoms. Table 2.6 summarizes the pharmacokinetics of all PPI 
drugs (Fock et al, 2008). 
 
Table 2.6: Pharmacokinetics of PPIs 
Parameter Esomeprazole  Lansoprazole  Omeprazole  Pantoprazole  Rabeprazole 
Bioavailability 90%  80%-85%  30%-40%  77%  52% 
Time to peak 
plasma 
concentration 
1.5 hours  1.7 hours  0.5-3.5 hours  2.5 hours  2-5 hours 
Half-life 
(plasma) 
1.2-1.5 hours  1.5 hours  0.5-1 hour  1 hour  1-2 hours 
Major 
cytochrome 
P450 pathway  CYP2C19  
CYP3A,  
CYP2C19 CYP2C19  CYP2C19  
CYP3A 
CYP2C19 
Protein binding 97%  97%  95%  98%  96.3% 
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2.8 Clinical Efficacy of PPI drugs 
All double blind randomized studies that were published comparing two or more 
PPIs or doses for the treatment of acute gastroesophageal disease (GERD) were 
obtained. The prospective evaluations of measurable clinical efficacy such as healing 
of esophagitis or symptoms resolution were summarized in Appendix A.  
 
In one study comparing esomeprazole 40 mg, esomeprazole 20 mg and omeprazole 
20 mg once daily, pH > 4 was maintained for 16.8 hours, 12.7 hours and 10.5 hours 
respectively (Lind et al., 2000). In another study involving 2425 patients with erosive 
esophagitis, esomeprazole 40 mg and omeprazole 20mg were compared at 4 and 8 
weeks. At 4 weeks, 93.7% on those on esomeprazole and 84.3% of those on 
omeprazole were healed (Richter et al., 2001). One study with 1960 patients with 
erosive esophagitis, it was found that esomeprazole 40 mg, esomeprazole 20 mg and 
omeprazole 20 mg have healing rates of 94.1%, 89.9% and 86.9% respectively 
(Kahrilas et al., 2000). These studies were often cited as evidence of the superiority 
of esomeprazole in esophageal healing, but it should be noted that the dose is not 
comparable. A meta-analysis concluded that esomeprazole healed erosive esophagitis 
at significant higher rates than omeprazole (Edward et al., 2001). However, all the 
studies were funded by AstraZeneca and two out of the three authors are employed 
by AstraZeneca.  
 
In the only study that use comparable dosages of esomepazole and omeprazole at 40 
mg respectively, those taking esomeprazole maintained a gastric pH > 4 for a mean 
of 16.4 hours while those taking omeprazole maintained for 14.9 hours. However, its 
small sample size of 114 patients limits its validity (Rohss et al., 2002). 
